TY - JOUR
T1 - Long-Term Prognostic Value of 82Rb PET/CT–Determined Myocardial Perfusion and Flow Reserve in Cancer Patients
AU - Fox, Josef J.
AU - Mauguen, Audrey
AU - Ito, Kimiteru
AU - Gupta, Dipti
AU - Yu, Alice
AU - Schindler, Thomas H.
AU - Strauss, H. William
AU - Schöder, Heiko
N1 - Publisher Copyright:
COPYRIGHT © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2023
Y1 - 2023
N2 - Myocardial flow reserve (MFR), derived from quantitative measurements of myocardial blood flow during PET imaging, provides prognostic information on patients with coronary artery disease (CAD), but it is not known if this also applies to cancer patients with a competing risk for mortality. Methods: To determine the prognostic value of MFR in patients with cancer, we designed a retrospective cohort study comprising 221 patients with known or suspected CAD (median age, 71 y; range, 41–92 y) enrolled between June 2009 and January 2011. Most patients were referred for perioperative risk assessment. Patients underwent measurement of myocardial blood flow at rest and during pharmacologic stress, using quantitative 82Rb PET imaging. They were divided into early-stage versus advanced-stage cancer groups based on cancer histopathology and clinical state and were further stratified by myocardial perfusion summed stress score, summed difference score, and calculated MFR. Overall survival (OS) was assessed using the Kaplan–Meier estimator, and Cox proportional-hazards regression helped identify independent predictors for OS. Results: During a follow-up of 85.6 mo, 120 deaths occurred. MFR, summed difference score, and cancer stage were significantly associated with OS. In the age-adjusted Cox hazard multivariable analysis, MFR and cancer stage remained independent prognostic factors. MFR combined with cancer stage enhanced OS discrimination. The groups had significantly different outcomes (P, 0.001), with 5-y OS of 88% (MFR $ 1.97 and early-stage), 53% (MFR, 1.97 and early-stage), 33% (MFR $ 1.97 and advanced-stage), and 13% (MFR, 1.97 and advanced-stage). Conclusion: Independent of cancer stage, MFR derived from quantitative PET was prognostic of OS in our cohort of cancer patients with known or suspected CAD. Combining these 2 parameters enhanced discrimination of OS, suggesting that MFR improves risk stratification and may serve as a treatment target to increase survival in cancer patients.
AB - Myocardial flow reserve (MFR), derived from quantitative measurements of myocardial blood flow during PET imaging, provides prognostic information on patients with coronary artery disease (CAD), but it is not known if this also applies to cancer patients with a competing risk for mortality. Methods: To determine the prognostic value of MFR in patients with cancer, we designed a retrospective cohort study comprising 221 patients with known or suspected CAD (median age, 71 y; range, 41–92 y) enrolled between June 2009 and January 2011. Most patients were referred for perioperative risk assessment. Patients underwent measurement of myocardial blood flow at rest and during pharmacologic stress, using quantitative 82Rb PET imaging. They were divided into early-stage versus advanced-stage cancer groups based on cancer histopathology and clinical state and were further stratified by myocardial perfusion summed stress score, summed difference score, and calculated MFR. Overall survival (OS) was assessed using the Kaplan–Meier estimator, and Cox proportional-hazards regression helped identify independent predictors for OS. Results: During a follow-up of 85.6 mo, 120 deaths occurred. MFR, summed difference score, and cancer stage were significantly associated with OS. In the age-adjusted Cox hazard multivariable analysis, MFR and cancer stage remained independent prognostic factors. MFR combined with cancer stage enhanced OS discrimination. The groups had significantly different outcomes (P, 0.001), with 5-y OS of 88% (MFR $ 1.97 and early-stage), 53% (MFR, 1.97 and early-stage), 33% (MFR $ 1.97 and advanced-stage), and 13% (MFR, 1.97 and advanced-stage). Conclusion: Independent of cancer stage, MFR derived from quantitative PET was prognostic of OS in our cohort of cancer patients with known or suspected CAD. Combining these 2 parameters enhanced discrimination of OS, suggesting that MFR improves risk stratification and may serve as a treatment target to increase survival in cancer patients.
KW - cancer
KW - myocardial flow reserve
KW - quantitative myocardial perfusion imaging
KW - rubidium PET
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85159241925&partnerID=8YFLogxK
U2 - 10.2967/jnumed.122.264795
DO - 10.2967/jnumed.122.264795
M3 - Article
C2 - 36604182
AN - SCOPUS:85159241925
SN - 0161-5505
VL - 64
SP - 791
EP - 796
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 5
ER -